1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Sarilumab (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Sarilumab (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

  • December 2014
  • -
  • GlobalData
  • -
  • 87 pages

Summary

Table of Contents

Search Inside

Sarilumab (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Summary

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

Regeneron and Sanofi’s sarilumab is the first fully-human mAb against IL-6, and is in Phase III of development for RA. Sarilumab is directed against IL-6R and reduces inflammation, thus preventing the joint damage that is common in RA. Although Actemra is an anti-IL6 mAb currently approved for RA, this biologic agent is a recombinant human mAb and does not offer the same safety advantages of a fully-human mAb.

Scope

- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Sarilumab including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Sarilumab for the top 8 countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Sarilumab performance.
- Obtain sales forecast for Sarilumab from 2013-2023 in top 8 countries (the US, France, Germany, Italy, Spain, the UK and Japan and Australia).

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • January 2017
  • by GlobalData

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025 Summary Systemic Lupus Erythematosus (SLE) is a systemic inflammatory autoimmune disease ...

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • January 2017
  • by GlobalData

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Colorectal Cancer (CRC) Market, considering the sales of both branded treatments and generic chemotherapy, is expected ...

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • January 2017
  • by GlobalData

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025 Summary Ulcerative Colitis (UC) is a type of chronic IBD that causes inflammation and ulcers in the innermost lining of ...

Hnscc: Kol Insight - 2017

March 2017 $ 8355

Download Unlimited Documents from Trusted Public Sources

Opioid Market and Digestive System Disorder Statistics in the US

  • April 2017
    20 pages
  • Opioid  

    Digestive Syste...  

  • United States  

View report >

Therapy Market in the US

  • April 2017
  • Therapy  

  • United States  

View report >

Therapy Market and Targeted Therapy Market in the UK

  • April 2017
    77 pages
  • Therapy  

    Targeted Therap...  

    Digestive Syste...  

  • United Kingdom  

View report >

Cranberry Industry

13 days ago

Diabetes Statistics

17 days ago

Related Market Segments :

Therapy
Arthritis

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.